- Open Access
Revisiting cefditoren for the treatment of community-acquired infections caused by human-adapted respiratory pathogens in adults
© The Author(s). 2018
- Received: 21 May 2018
- Accepted: 24 September 2018
- Published: 2 November 2018
Fifteen years after its licensure, this revision assesses the role of cefditoren facing the current pharmacoepidemiology of resistances in respiratory human-adapted pathogens (Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae and Moraxella catarrhalis). In the era of post- pneumococcal conjugate vaccines and in an environment of increasing diffusion of the ftsI gene among H. influenzae isolates, published studies on the cefditoren in vitro microbiological activity, pharmacokinetic/pharmcodynamic (PK/PD) activity and clinical efficacy are reviewed. Based on published data, an overall analysis is performed for PK/PD susceptibility interpretation. Further translation of PK/PD data into clinical/microbiological outcomes obtained in clinical trials carried out in the respiratory indications approved for cefditoren in adults (tonsillitis, sinusitis, acute exacerbation of chronic bronchitis and community-acquired pneumonia) is commented. Finally, the role of cefditoren within the current antibiotic armamentarium for the treatment of community respiratory tract infections in adults is discussed based on the revised information on its intrinsic activity, pharmacodynamic adequacy and clinical/bacteriological efficacy. Cefditoren remains an option to be taken into account when selecting an oral antibiotic for the empirical treatment of respiratory infections in the community caused by human-adapted pathogens, even when considering changes in the pharmacoepidemiology of resistances over the last two decades.
Introduction of pneumococcal conjugate vaccines has modified the susceptibility profile of circulating Streptococcus pneumoniae in the community
Antibiotic pressure in the community has facilitated the emergence and diffusion of β-lactamase negative ampicillin-resistant (BLNAR) and β-lactamase positive amoxicillin/clavulanate-resistant (BLPACR) H. influenzae isolates, implying resistance to several oral β-lactams
The review of the high number of pharmacodynamic studies carried out with cefditoren since its licensure shows that cefditoren maintains its pharmacodynamic activity against the most prevalent bacterial isolates from community respiratory infections.
Among the complex niche representing the nasopharyngeal microbiota, four bacterial species have in common humans as exclusive commensals, with no animal or environmental reservoirs contributing to their life-cycle: Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae and Moraxella catarrhalis, with different turnover rates in nasopharynx. Human to human transmission, which occurs via respiratory droplets, is critical for them to persist. Alterations in the ecological niche or migrations to other niches are responsible for their change to human-adapted pathogens causing pharyngotonsillitis (S. pyogenes) or otitis, rhinosinusitis and lower respiratory tract infections (LRTIs) (S. pneumoniae, H. influenzae and M. catarrhalis). Thus, apart from their commensalism, they exhibit direct pathogenicity.
Additionally, the indirect pathogenicity of H. influenzae and M. catarrhalis protecting S. pyogenes and S. pneumoniae from the action of some β-lactam antibiotics by means of their β-lactamases has been described. In vivo, formation of biofilms (which are larger when S. pneumoniae and H. influenzae or M. catarrhalis are present than when only one species is alone)  favors indirect pathogenicity and intracellular antibiotic deactivation . The coexistence of susceptible and resistant cells within these bacterial communities increases the opportunity for horizontal gene transfer during antibiotic selection pressure . This gene transfer depends on the duration of carriage: strains with longer duration of carriage have a greater risk of antibiotic exposure and thus, greater risk for acquiring resistance . In turn, resistance implies fitness advantages for bacteria in the presence of antibiotics, favoring spread of resistant isolates within the community.
Antibiotic resistance significantly impacts on patient’s illness burden in the community, and patients with laboratory-confirmed antibiotic-resistant respiratory tract infections (RTIs) are likely to experience delayed recovery following antibiotic treatment . In the era prior to licensure of conjugate pneumococcal vaccines (PCV), antibiotic use was the basic and exclusive force behind resistance patterns in bacteria isolated from community-acquired infections [5–7] despite of descriptions of correlations between pneumococcal resistance and educational level, climate and proportion of young people in the population . At different geographical areas, positive correlations between percentages of macrolide resistance in S. pneumoniae and S. pyogenes were described , and resistance was associated with macrolide consumption (mainly compounds exhibiting long half-life) [7, 9, 10]. Similarly, β-lactam consumption (mainly oral 2nd generation cephalosporins) was associated with penicillin resistance in S. pneumoniae . A global ecological relationship of resistance between penicillin-resistant S. pneumoniae, erythromycin-resistant S. pneumoniae, erythromycin-resistant S. pyogenes and ampicillin-resistant H. influenzae was described , reinforcing the idea of consumption of certain antibiotics as driver of resistances in human-adapted respiratory pathogens in the community.
In the post-vaccine era, this situation has completely changed with a decrease in the prevalence of penicillin-resistant S. pneumoniae (with lower changes in erythromycin resistance in both streptococcal species) and the emergence of ampicillin-resistant phenotypes not related to β-lactamase production in H. influenzae. These complex dynamics have been influenced by different factors in the present century: vaccine pressure and natural serotypes fluctuations, co-selection of resistances, selection of co-resistances, and antibiotic consumption patterns according to the population structure , among others.
Although they have in common being human-adapted pathogens colonizing the nasopharynx as their natural ecological niche, not all of them have equally responded (on the basis of non-susceptibility emergence and dissemination) to the preventive and therapeutic measures introduced. Spread of resistance in S. pyogenes and M. catarrhalis, limited to certain antibiotics, contrasts with emergence and spread of resistance to β-lactams and macrolides in S. pneumoniae and H. influenzae, driving to more complex scenarios.
S. pyogenes is uniformly susceptible to β-lactams and, among oral cephalosporins, cefditoren exhibits the highest intrinsic activity, with MIC90 values ≤0.06 mg/l. [13–15] Resistance to erythromycin (implying resistance to clarithromycin and azithromycin) varies from < 10% (USA, Baltic countries, Romania), to 10–20% (Poland, Czech Republic, Spain) and 25–35% (Slovakia, Hungary, Hong Kong), being up to 93.5% in China [13, 16–20].
Almost 100% strains of M. catarrhalis are β-lactamase producers ; MIC90 values of cefditoren (range from 0.25 to 0.5 mg/l) are lower than those of amoxicillin/clavulanic acid (range from 0.25 to 2 mg/l) and cefuroxime (range from 2 to 8 mg/l [14, 15, 22, 23].
Streptococcus pneumoniae: the post-PCV13 scenario
Based on the most common pediatric serotypes, PCV7 was developed and introduced for universal immunization of healthy children in most developed countries in 2000–1. However, detection of emerging new serotypes in the late PCV7 period led to the inclusion of six additional serotypes in the new PCV13 in 2010. Since then, decreases in invasive pneumococcal disease (IPD), not only in children but also in adults due to herd effect [24–27], as well as in PCV13 serotypes involved in non-invasive diseases, have been described [25, 27]. Although some studies [28–30], but not others [24, 31], have found slight increases in non-PCV13 serotypes causing IPD, individually none of the non-PCV13 serotypes has shown a significant increase , in contrast to the increase in serotype 19A (with its associated resistant sequence types ) after PCV7 implementation [33–35].
Since susceptibility is strongly linked to serotypes, targeting prevalent capsular serotypes with PCVs is extremely effective in reducing resistant infections . While in countries that lack a significant PCV coverage > 40% isolates are penicillin-resistant , in those where PCV13 was introduced, antibiotic–nonsusceptible IPD has decreased in all age groups [24, 25, 37], as well as antibiotic–nonsusceptible isolates colonizing the nasopharynx in children . Data from 2013 in USA showed that the proportions of non-susceptible IPD cases were around 10% for penicillin and 33% for macrolides in children, and around 6 and 28%, respectively, in adults . These high nonsusceptibility rates to macrolides in USA are lower than those found in a surveillance from 11 Asian countries reporting a mean percentage of resistance to erythromycin as high as 72.7%, with the highest rates in China (96.4%), Taiwan (84.9%) and Vietnam (80.7%) . Another report from Thailand confirmed high resistance rates to erythromycin (51.3%)  in Asia.
Few pneumococcal surveillance studies including cefditoren among the antimicrobials tested have been published in the last 5 years. Studies published in the previous decade (2007–2010) (pre-PCV13 era) showed that among penicillin-susceptible isolates, cefditoren MIC90 values ranged from ≤0.03 to 0.06 mg/l. [14, 15, 41–48] Against penicillin-intermediate strains, values increased to 0.25–0.5 mg/l while among penicillin-resistant strains, they ranged from 0.5 to 1 mg/l. [14, 15, 41–48] For amoxicillin and cefuroxime, MIC90 values for penicillin-susceptible isolates ranged from 0.12 to 0.25 mg/l [14, 15, 41–47] for cefuroxime and from 0.03 to 0.25 mg/l for amoxicillin [14, 15, 42–47]. For penicillin-intermediate strains, values ranged from 4 to 8 mg/l [14, 15, 41–47] for cefuroxime and from 1 to 4 mg/l for amoxicillin [14, 15, 42–47], while for penicillin-resistant strains, they ranged from 8 to 32 mg/l for cefuroxime and from 8 to ≥16 mg/l for amoxicillin [14, 15, 41–47]. All these studies showed that cefditoren exhibited the highest in vitro intrinsic activity compared with other oral β-lactams [14, 15, 41–48]. Other studies in the last decade not distributing strains by penicillin susceptibility also showed MIC50/MIC90 values of cefditoren lower than those of other oral cephalosporins: ≤0.06 and 1 mg/l, respectively, in a study in 11 Asian countries , and ≤ 0.015 and 0.125 mg/l, respectively, in a Spanish surveillance . The last surveillance study (including cefditoren among the antimicrobials tested) found in the literature, a surveillance study in Japan, showed MIC50/MIC90 values of cefditoren of 0.125/0.5 mg/l. 
The highest activity of cefditoren was also demonstrated in an in vitro study comparing cidal activity of serum achievable concentrations of third-generation oral cephalosporins (cefditoren, cefpodoxime, cefdinir, and cefixime), using cefotaxime as control drug, against pneumococcal strains distributed by cefotaxime MICs (0.5 to 2 mg/l) . Against strains with cefotaxime MIC > 1 mg/l, only cefditoren (at 0.5–1 mg/l concentrations, which are lower than the maximum concentration in serum) achieved > 90% reduction of initial inocula . Another study comparing cidal activity of cefditoren with that of other β-lactams (amoxicillin/clavulanic acid, cefuroxime, cefixime and cefpodoxime) and levofloxacin showed that cefditoren was the only agent achieving, at concentrations equal to 2× MIC, significant bactericidal activity (≥3 log reduction of initial inocula within 4 h) against penicillin- susceptible and resistant S. pneumoniae .
These studies, carried out in the pre-PCV13 era, demonstrated the high comparative intrinsic activity (in terms of MIC and bactericidal activity) of cefditoren against S. pneumoniae. In the post-PCV13 era, considering that, as stated, the vaccine implementation has reduced the prevalence of pneumococcal resistance in the community [24, 25, 36–38] by targeting most resistant serotypes, the number of penicillin-resistant isolates with high cefditoren MICs (i.e > 0.25 mg/l) should had necessarily been reduced.
Traditionally, β-lactamase production was the mechanism of resistance to aminopenicillins in non-typeable H. influenzae (NTHi). However, antibiotic pressure by amoxicillin/clavulanate and oral cephalosporins contributed to the spread of non-enzymatic resistance mechanisms linked to the ftsI gene . In the past decade, many countries experimented a rapid increase in genetically-defined β-lactamase negative ampicillin-resistant (gBLNAR) isolates, accounting for 15–30% of all isolates, among others, in Europe, Australia and USA, with up to 50% in Japan [54–59]. In Spain BLNAR isolates increased in parallel with decreases in β-lactamase producing-isolates , and the last published study determining susceptibility of invasive H. influenzae isolates showed up to 19% gBLNAR isolates compared with 16.9% isolates resistant due to β-lactamase production . Similarly, a recent report from Japan showed the lower percentage of ampicillin-resistant strains due to β-lactamase production (5.6%) than to BLNAR (37.2%) among NTHi respiratory isolates . In Sweden, the increase in β-lactam resistance among invasive H. influenzae isolates has also been attributed to the significant increase in BLNAR isolates .
Isolates exhibiting both mechanisms of resistance (β-lactamase production and mutations in the ftsI gene), the so-called β-lactamase positive amoxicillin/clavulanic acid-resistant (BLPACR) isolates, account for lower proportions than BLNAR isolates [16, 58, 60], also among invasive isolates , generally with percentages lower than 5%. However, higher and overtime constant rates of BLPACR isolates  and marked increases from 2011 to 2013, reaching 19% in China , have been reported.
Published data show that both against β-lactamase positive and negative NTHi isolates, MIC90 values of cefditoren (range from ≤0.03 to 0.06 mg/l) are 5–7 dilutions lower than those of amoxicillin/clavulanic acid or cefuroxime (MIC90 range from 1 to 8 mg/l for both compounds) [14, 15, 22, 41, 44]. PBP3 modifications subsequent to ftsI gene mutations could decrease susceptibility not only to aminopenicillins but also to some oral cephalosporins as cefaclor or cefuroxime [60, 61, 64]. Against BLNAR isolates MIC90 values were 0.03–0.06 mg/l for cefditoren; values markedly lower than those for amoxicillin/clavulanic acid (4 mg/l) and for cefuroxime (2–16 mg/l) [14, 15, 65]. Recent reports have confirmed the high intrinsic activity of cefditoren against NTHi independently of the production of β-lactamase or the BLNAR phenotype [66, 67] or the presence of both resistance mechanisms . On the other hand, NTHi can be considered intrinsically resistant to macrolides, being its resistance associated with the presence of efflux pumps in virtually all strains .
Comparative intrinsic activity: Range (mg/l) of MIC50 and MIC90 from published studies
Streptococcus pyogenes a
Streptococcus pneumoniae b
2 - ≥16
8 - ≥16
Moraxella catarrhalis (β-lactamase positive)
Revisiting cefditoren pharmacokinetic/pharmacodynamic (PK/PD) data to interpret susceptibility [69–71]
Summary of PK/PD studies carried out with cefditoren (CDN)
Type of study
Killing curves in the presence/absence of human albumin (Cmax: 4.1 mg/l)
(CDN MICs: 0.12–0.5 mg/l)
The activity of cefditoren should not be linked exclusively with the theoretical unbound fraction extrapolated from the plasma concentration.
Killing curves in the presence/absence of human albumin or human serum (Cmax: 4.1 mg/l)
(CDN MICs: 0.12–0.5 mg/l)
The presence of 90% human serum did not limit bactericidal activity as did the use of concentrations similar to free-drug.
In vitro computerized pharmacodynamic simulation in the presence of 75% human serum
(CDN MICs: 0.25–0.5 mg/l)
Cefditoren physiological concentrations exerted antibacterial activity against strains exhibiting MICs of 0.25 and 0.5 m/l under protein binding conditions similar to those in humans (experimentally measured)
In vitro computerized pharmacodynamic simulation (total vs. free concentrations)
H. influenzae (including BLNAR and BLPACR)
The experimental bactericidal activity of cefditoren (both total and free concentrations) was maintained over the dosing interval regardless of the presence of mutation in the ftsI gene or β-lactamase production, in contrast to co-amoxiclav.
In vitro computerized pharmacodynamic simulation
S. pneumoniae (amoxicillin MIC > penicillin MIC)
(CDN MICs: 0.12–1 mg/l)
Bactericidal activity at 12 and 24 h was obtained against all strains with cefditoren, but not with comparators.
In vitro computerized pharmacodynamic simulation
S. pneumoniae (mixed inocula)
(CDN MICs: 0.015, 0.5, 1 mg/l)
Against penicillin resistant strains, cefditoren (but not comparators) decreased the initial bacterial load all along the simulation, without regrowth and with lower selection of resistant subpopulations
In vitro computerized pharmacodynamic simulation
H. influenzae (including BLNAR and BLPACR)
Cefditoren exhibited the highest bactericidal activity maintained over time against ampicillin-resistant H. influenzae, regardless of beta-lactamase production and/or BLNAR phenotype.
In vitro computerized pharmacodynamic simulation
H. influenzae β−
H. influenzae β+
Cefditoren offered higher antibacterial effect than comparators due to its higher activity against beta-lactamase-producing strains and those carrying ftsI gene mutations. BLNAR and BLPACR strains were selected by cefuroxime and co-amoxiclav, respectively.
In vitro computerized pharmacodynamic simulation
H. influenzae β+
Cefditoren (but not comparators) completely countered indirect pathogenicity and eradicated S. pyogenes and both H. influenzae strains.
In vitro computerized pharmacodynamic simulation in media containing ftsI DNA
H. influenzae β−
H. influenzae β+
Cefditoren (but not co-amoxiclav) was bactericidal and countered intrastrain ftsI gene diffusion
In vitro study assessing by flow cytometry the deposition/binding of components of the complement system to bacterial cells
Increased recognition of S. pneumoniae by the complement system in the presence of sub-inhibitory concentrations of cefditoren
Mice sepsis model (pre-immunized vs. non pre-immunized mice)
(CDN MICs: 1, 2, 4 mg/l)
In non pre-immunized animals, t > MIC values for CDN of approximately 35% (total) and approximately 19% (free) were associated with 100% survival, with lower values in pre-immunized animals
Monte Carlo simulation
Coverage with total concentrations:
a. criterion of 40% t > MIC: MICs ≤0.5 mg/l
b. criterion of 33% t > MIC: MICs ≤0.5 mg/l
Coverage with extrapolated free concentrations:
a. criterion of 40% t > MIC: MICs ≤0.12 mg/l
b. criterion of 33% t > MIC: MICs ≤0.25 mg/l
One remarkable fact of cefditoren pharmacokinetics is the different bioavailability in the fast/fed states. The administration of cefditoren-pivoxil following a high fat meal results in a 70% increase in mean AUC and 50% increase in mean Cmax compared to administration of cefditoren-pivoxil in the fasted state . Therefore, conclusions of pharmacodynamic studies are different depending on the fed/fast condition of subjects included [85, 88], and for this reason the prescribing information recommends cefditoren intake with meals to enhance absorption .
Essential points guiding susceptibility interpretation are the accepted cut-off values of the PK/PD index predicting efficacy for β-lactams (percentage of dosing interval that antibiotic concentrations exceed the MIC; t > MIC), set at 40% for clinical cure and at 33% for bacteriostasis [89, 90]. The FDA and CLSI definitions of the “susceptible” category involve the bacteriostatic endpoint (33% t > MIC) since “susceptibility” is defined as the likely inhibition of the pathogen if the antimicrobial compound reaches the concentration usually achievable after administration of the recommended dose [91, 92].
Several susceptibility breakpoints have been proposed for cefditoren [93–95], ranging from ≤0.125 mg/l (included in the FDA prescribing information)  to ≤0.5 mg/l (approved by the Reference Member State, Spain, during the Mutual Recognition Procedure in Europe) . In vivo, a pneumococcal sepsis model infecting mice with isolates exhibiting exceptionally high MICs of cefditoren (1–2 mg/l) exceeding the proposed susceptibility breakpoints, showed that cefditoren t > MIC of ≈35% (free t > MIC of ≈20%) produced 100% survival compared with 0% survival in untreated animals . A free t > MIC value of ≈20% was also related to > 99.9% reduction in bacterial load of two different pneumococcal isolates (MICs of 0.25 μg/ml) in an in vitro pharmacodynamic simulation with physiological albumin concentrations and 86% protein binding rate in the device . These two studies demonstrated that the limitation of the activity of cefditoren by protein binding is far from absolute, being the activity of total concentrations in the presence of albumin/serum higher than the one exhibited by calculated free concentrations.
The range of proposed breakpoints (from ≤0.125 to ≤0.5 mg/l) is well supported by a Monte Carlo simulation of cefditoren investigating coverage by concentrations achieved in serum after 400 mg oral dosing (after meals)  according to different criteria: a) By using total concentrations and the bacteriostatic criterion (33% t > MIC), cefditoren covered strains inhibited by MICs up to 0.5 mg/l, b) By using extrapolated free drug concentrations and 33% t > MIC, coverage was achieved for strains inhibited by MICs up to 0.25 mg/l, and c) By using extrapolated free drug concentrations and the criterion of 40% t > MIC, strains exhibiting MICs up to 0.12 mg/l were covered .
Ranges of susceptibility against penicillin-susceptible (≤0.06 mg/l), penicillin-intermediate and penicillin-resistant (≥2 mg/l) pneumococcal isolates, calculated with MIC distributions from published studies [41–45] by applying CLSI breakpoints (amoxicillin, cefuroxime) and the three proposed breakpoints for cefditoren
Penicillin susceptible isolates
Penicillin intermediate isolates
Penicillin resistant isolates
Amoxicillina (≤2 mg/l)
Cefuroxime (≤1 mg/l)
≤ 0.125 mg/l
≤ 0.25 mg/l
≤ 0.5 mg/l
Pharmacodynamic breakpoints can be related with bacterial eradication and subsequent therapeutic outcome . For this reason, microbiological evaluation in clinical trials provides the best quality data to support breakpoints. However, despite the percentage of resistance in the community, in a clinical trial it is difficult to have enough number of patients infected by resistant bacteria to reach conclusions. To overcome this, data from microbiological evaluation in clinical trials of community-acquired pneumonia (CAP) and acute exacerbations of chronic bronchitis (AECB) carried out with cefditoren were pooled and analyzed in order to increase the number of evaluable patients. In that analysis, 100% penicillin non-susceptible (MIC ≥0.12 mg/l) isolates of S. pneumoniae in the cefditoren 400 mg group (n = 20), 16 of 19 (84.2%) strains in the 200 mg group, and 16 of 17 (94.1%) strains in the comparator group were eradicated or presumably eradicated . Among S. pneumoniae isolates showing penicillin resistance (MIC ≥2 mg/l), 17 out of 18 (94.4%) isolates from patients in both cefditoren arms were eradicated or presumably eradicated compared with 10 out of 11 (90.9%) in the comparator group .
Percentage of responders in the clinical evaluation of cefditoren efficacy in clinical trials. Published data
Cefditoren 200 mg bid
Cefditoren 400 mg bid
93.4 – 98.6
87.2 – 91.8
In pharyngotonsillitis studies, since all patients included in clinical trials had a pre-treatment positive culture, the relationship between the microbiological and clinical response obtained was investigated. The percentage of favorable clinical response was significantly higher (p < 0.01) in patients showing bacteriological eradication (≥98.5%) than in those showing bacteriological persistence (≤51.4%) , evidencing the relationship between microbiological and clinical responses. Overall, the post-treatment microbiological response (eradication) was significantly (p < 0.01) higher with cefditoren versus penicillin (used as comparator): 90.4% versus 82.7% at the end-of-treatment visit, and 84.7% versus 76.7% at the end of follow up visit, respectively . In a recent revision of eight published clinical studies, failure rates with penicillin in the treatment of pharyngotonsillitis ranged from 14 to 40%, and one of the main reasons advocated by the author was penicillin inactivation by β-lactamases present in the environment produced by β-lactamase producing bacteria , as H. influenzae. This “indirect pathogenicity” was demonstrated in a pharmacodynamic simulation using a mixed inocula of S. pyogenes, penicillin-resistant S. pneumoniae, β-lactamase positive NTHi and a BLPACR strain exposed to simulated serum concentrations of amoxicillin, amoxicillin/clavulanic acid or cefditoren . Of the three compounds, cefditoren, stable to β-lactamases was the unique compound that completely countered the indirect pathogenicity and eradicated both β-lactamase positive organisms . For the BLPACR strain the accumulation of two resistance traits (β-lactamase production and ftsI gene) represented a competitive advantage in the presence of amoxicillin/clavulanic acid , this compound not being able to completely counter indirect pathogenicity as cefditoren did. These data acquire relevance since antibiotic-treated individuals are sources for spread of β-lactamase producing bacteria to other individuals , and carriage of H. influenzae has been associated with vaccination with PCVs .
Antibiotic degradation via β-lactamases enabling growth of susceptible cells in their vicinity [2, 112], even across species, has been demonstrated in other in vitro studies and in animal models, favoring S. pneumoniae growth in the presence of H. influenzae or M. catarrhalis [1, 2, 113]. In the context of biofilms, interactions between species are facilitated, and this may explain the tendency of different species to occur together , as H. influenzae and S. pneumoniae, which form a much larger biofilm together than either bacterium does on its own . This is one of the reasons for the increasing interest on biofilms in the investigational field. One of the major goals in modern clinical microbiology is the development of strategies capable of reducing biofilm infections related to chronic conditions due to the difficulty for antibiotics in eradicating bacteria within these structures (due to difficulties in reaching bacterial cells or diminished bacterial growth rate, leading to persistence). Microorganisms typically colonizing the human respiratory tract make full use of the biofilm strategy when causing non-invasive disease (chronic bronchitis, sinusitis and otitis).
In chronic bronchitis, antibiotic therapy overcomes the symptoms caused by waves of planktonic cells released from the biofilm during exacerbations of the disease but fails to eradicate infection as sessile cells are inherently less affected . Due to these facts not only time to eradication of symptoms is an endpoint in clinical trials with antibiotics against exacerbations, but also time to relapse is increasingly used as endpoint. In healthy lungs, there is a transient microbiome of micro-aspirated upper airway microbial flora being cleared by normal lung defense mechanisms . Chronic exposure to cigarette smoke results in higher loads of NTHi and S. pneumoniae in lungs , and these potential pathogenic microorganisms have been detected in approximately 25% of patients with chronic obstructive pulmonary disease (COPD) during stable disease . COPD and subsequent AECBs (with related presence of released planktonic cells) are associated with biofilms [120–123], with a relevant role for H. influenzae. In addition, COPD patients with frequent exacerbations show an increase in inflammation in the upper airways contributing to the progression of the disease . Antibiotics active against planktonic cells and able to interfere or decrease biofilm development may offer clinical advantages . Additionally, the use of antibiotics may also reduce inflammatory parameters . Cefditoren showed to interfere biofilm formation in a study comparing cefditoren (0.03 mg/l) with amoxicillin/clavulanic acid (1/0.5 mg/l) that concluded that both compounds were able to reduce biofilm formation by the 10 pneumococcal isolates tested, with significant higher reductions in the case of cefditoren . With respect to inflammation, one study comparing cefditoren and levofloxacin found that the use of both antimicrobials was associated with significant reductions of IL-6 and KL-6, two mediators of lung inflammation and epithelial damage [107, 127].
The acquisition of a new strain of H. influenzae (responsible for 13–50% of AECBs [128, 129]), S. pneumoniae or M. catarrhalis has been described as a fact increasing the risk of exacerbation . With respect to S. pneumoniae, it has been reported that new episodes occurring within the first 3 months after a previous episode show a high probability of being caused by the same strain, an important feature for election of empiric therapy . Based on its in vitro activity against human-associated respiratory pathogens (Table 1) and concentrations in bronchial mucosa of 0.56–1.04 mg/kg , cefditoren provides adequate focal coverage in AECB, as demonstrated by clinical trials (Table 4). One of the clinical trials of AECB treated with cefditoren investigated the relationship between the clinical and bacteriological response, and suggested that the response to the antibiotic was more rapidly seen in signs that depend on the bacterial location (more rapid and greater decrease over time in sputum volume, and purulence and rales and rhonchi) than in those depending in part on previous structural damage . In this trial, clinical success by key baseline pathogen was 84.0% vs. 82.5% for NTHi, and 92.3% vs. 81.3% for S. pneumoniae for cefditoren vs. cefuroxime, respectively .
Another mixed infection (mainly, S. pneumoniae and H. influenzae) involving biofilms is rhinosinusitis, where cefditoren has shown percentages of clinical efficacy similar to those of AECB at the end of treatment in clinical trials (Table 4).
Further non-clinical studies have corroborated the adequacy of cefditoren in the treatment of LRTIs. The TOM probability model was used to predict the likelihood of clinical success in AECB considering, among other factors, the likelihood of spontaneous resolution . The study concluded that fluoroquinolones, cefditoren and high doses of amoxicillin/clavulanic acid were the antimicrobials that highest predict clinical efficacy in the treatment of AECB in contrast to cefaclor and macrolides (with predictions not much higher than that of placebo) . These results are in accordance with a 15-year longitudinal study of COPD showing that macrolides were ineffective in eradicating H. influenzae .
Using the Delphi methodology to assess the consensus on the most appropriate strategy for acute LRTIs, 71% agreement was reached on the statement that empiric therapy with antibiotics characterized by a resistance profile above the 10–20% threshold and the non-protected β-lactams should be avoided . This, together with the TOM probability study  points to discard macrolides as treatment considering their lack of PK/PD activity against H. influenzae, a pathogen potentially involved. Consensus (78% agreement) was also reached on the need to use antibiotics able to target emergent BLNAR and BLPACR isolates to prevent intra-species diffusion of resistant strains when treating AECB . In vitro, cefditoren (in contrast to amoxicillin/clavulanic acid) demonstrated to counter intra-strain diffusion and spread of nonenzymatic resistance mechanisms (ftsI gene) in a pharmacodynamic simulation including several NTHi strains . Consensus (96% agreement) was also reached on the statement that among third-generation cephalosporins, cefditoren has a particularly balanced spectrum, the 400 mg dose every 12 h covering penicillin-resistant pneumococci .
Apart from the use of cefditoren in the treatment of mild to moderate CAP [87, 96], cefditoren may have a role as oral treatment following intravenous treatment with third generation cephalosporins. Among others, IDSA and ATS guidelines recommend a switch to oral antibiotics for the treatment of stable hospitalized patients with CAP as soon as the patient is improving [135, 136]. A very high consensus (93%) was reached in the Delphi-based analysis on the statement that cefditoren is the best switch for intravenous third generation cephalosporins (cefotaxime, ceftriaxone) because of the similar spectrum and the highest intrinsic activity . In this sense, cefditoren has been included as recommended drug for switch therapy after intravenous treatment with third generation cephalosporins in several documents [137–139], in contrast to cefuroxime which does not provide the required high intrinsic activity and adequate pharmacodynamics .
In a meta-analysis of six randomized clinical trials including 1219 patients hospitalized with moderate to severe CAP, the authors concluded that early conversion to oral antibacterial treatment appeared to be as effective as traditional intravenous treatment and was associated with fewer drug-related adverse events and shorter hospital stays , thus also reducing associated costs. In the treatment of LRTIs, the price of the antibiotic therapy does not represent the most affecting health care cost. In the Delphi-based approach, high consensus was reached on the statement that the price of the initial antibiotic therapy does not represent the most affecting health care cost (88% consensus) . Switch from parenteral to oral antibiotic therapy reduces length and costs of hospitalization, and the risk of hospital-acquired infections, improving patient’s quality of life as well (100% agreement) . On the contrary, indirect costs related to failures by resistant bacteria may have considerable influence . In this sense, in a retrospective analysis of CAP treatment, significantly higher percentages of treatment failures were obtained in metropolitan areas with ≥25% resistance than in those with lower resistance rates, with an increase in 33% of costs in the areas with resistance rates higher than 25% [141, 142]. In a cost-effective analysis carried out in three countries, first-line treatment effective against the major CAP pathogens (including strains resistant to other antimicrobials) resulted in better clinical outcomes and lower treatment costs .
In addition to monetary costs, selection of resistance has a social cost derived from the impact of resistance in future infections in the community. The challenge for institutions and individual clinicians is to consider the potential impact of each antibiotic prescription on resistance . Low potential of resistance selection and ecological consideration for human microbiota are two desirable features in antibiotic treatment . Non-clinical studies carried out with cefditoren, which constitute the largest documentation in the ecological field for all antimicrobials, suggest that cefditoren possesses advantages with respect to its ability for countering diffusion and selection of resistance  in S. pneumoniae [78, 81] and H. influenzae [76, 79–82].
Theoretically, the 15 years passed since its licensure should not have harmed the intrinsic activity of cefditoren against the respiratory human-adapted pathogens but have probably improved it somewhat since, maintaining its high activity against H. influenzae (regardless the increase of BLNAR and BLPACR isolates), M. catarrhalis and S. pyogenes, the percentage of penicillin-resistant S. pneumoniae has decreased, at least in countries where PCVs have been included in vaccination calendars. Due to this, H. influenzae has acquired more relevance, and the good activity of cefditoren against this species and its ability to counter diffusion of the ftsI gene and the indirect pathogenicity by β-lactamase producing strains, strengths its value within the antibiotic armamentarium. Despite there is a lack of CLSI/EUCAST susceptibility breakpoints, the first decade of the present century has provided a plethora of pharmacodynamic studies with cefditoren, focused not only on activity/efficacy prediction but also on countering selection and diffusion of resistance, which support its role in the treatment of infections caused by respiratory human-adapted pathogens, thus filling the traditional gap remaining in antibiotic development  by an active post-marketing investigational task [147, 148].
This review was performed with a grant from Tedec-Meiji Pharma S.A. (Madrid, Spain). The sponsor has had no influence on the content of the manuscript.
Availability of data and materials
Not applicable. All data included in the review is published and referenced.
The three authors contributed in the collection of published articles with cefditoren and writing of the manuscript. All authors read and approved the final manuscript.
Ethics approval and consent to participate
Consent for publication
Not applicable. All data included in the review is published and referenced.
PRISM-AG SL have received grants from Tedec-Meiji Pharma S.A. (Madrid, Spain) for the performance of pharmacodynamic studies with cefditoren. MJG and LA are members of the Research Department of PRISM-AG.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Weimer KE, Juneau RA, Murrah KA, Pang B, Armbruster CE, Richardson SH, et al. Divergent mechanisms for passive pneumococcal resistance to β-lactam antibiotics in the presence of Haemophilus influenzae. J Infect Dis. 2011;203:549–55.PubMedView ArticlePubMed CentralGoogle Scholar
- Sorg RA, Lin L, van Doorn GS, Sorg M, Olson J, Nizet V, et al. Collective resistance in microbial communities by intracellular antibiotic deactivation. PLoS Biol. 2016;14:e2000631.PubMedView ArticlePubMed CentralGoogle Scholar
- Lehtinen S, Blanquart F, Croucher NJ, Turner P, Lipsitch M, Fraser C. Evolution of antibiotic resistance is linked to any genetic mechanism affecting bacterial duration of carriage. Proc Natl Acad Sci U S A. 2017;114:1075–80.PubMedView ArticlePubMed CentralGoogle Scholar
- Van Hecke O, Wang K, Lee JJ, Roberts NW, Butler CC. The implications of antibiotic resistance for patients’ recovery from common infections in the community: a systematic review and meta-analysis Clin Infect Dis 2017 doi: https://doi.org/10.1093/cid/cix233. [Epub ahead of print].PubMedView ArticlePubMed CentralGoogle Scholar
- García-Rey C, Fenoll A, Aguilar L, Casal J. Effect of social and climatological factors on antimicrobial use and Streptococcus pneumoniae resistance in different provinces in Spain. J Antimicrob Chemother. 2004;54:465–71.PubMedView ArticlePubMed CentralGoogle Scholar
- Boccia D, Alegiani SS, Pantosti A, Moro ML, Traversa G. The geographic relationship between the use of antimicrobial drugs and the pattern of resistance for Streptococcus pneumoniae in Italy. Eur J Clin Pharmacol. 2004;60:115–9.PubMedView ArticlePubMed CentralGoogle Scholar
- Cizman M, Pokorn M, Seme K, Orazem A, Paragi M. The relationship between trends in macrolide use and resistance to macrolides of common respiratory pathogens. J Antimicrob Chemother. 2001;47:475–7.PubMedView ArticlePubMed CentralGoogle Scholar
- Gómez-Lus R, Granizo JJ, Aguilar L, Bouza E, Gutierrez A, García-de-Lomas J. Is there an ecological relationship between rates of antibiotic resistance of species of the genus Streptococcus? The Spanish surveillance Group for Respiratory Pathogens. J Clin Microbiol. 1999;37:3384–6.PubMedPubMed CentralGoogle Scholar
- Granizo JJ, Aguilar L, Casal J, García-Rey C, Dal-Ré R, Baquero F. Streptococcus pneumoniae resistance to erythromycin and penicillin in relation to macrolide and beta-lactam consumption in Spain (1979-1997). J Antimicrob Chemother. 2000;46:767–73.PubMedView ArticlePubMed CentralGoogle Scholar
- Granizo JJ, Aguilar L, Casal J, Dal-Ré R, Baquero F. Streptococcus pyogenes resistance to erythromycin in relation to macrolide consumption in Spain (1986-1997). J Antimicrob Chemother. 2000;46:959–64.PubMedView ArticlePubMed CentralGoogle Scholar
- Pérez-Trallero E, García-de-la-Fuente C, García-Rey C, Baquero F, Aguilar L, dal-Ré R, et al. Geographical and ecological analysis of resistance, coresistance, and coupled resistance to antimicrobials in respiratory pathogenic bacteria in Spain. Antimicrob Agents Chemother. 2005;49:1965–72.PubMedView ArticlePubMed CentralGoogle Scholar
- Baquero F, Baquero-Artigao G, Cantón R, García-Rey C. Antibiotic consumption and resistance selection in Streptococcus pneumoniae. J Antimicrob Chemother. 2002;50(Suppl S2):27–37.PubMedView ArticlePubMed CentralGoogle Scholar
- Gracia M, Díaz C, Coronel P, Gimeno M, García-Rodas R, Rodríguez-Cerrato V, et al. Antimicrobial susceptibility of Streptococcus pyogenes in central, eastern, and Baltic European countries, 2005 to 2006: the cefditoren surveillance program. Diagn Microbiol Infect Dis. 2009;64:52–6.PubMedView ArticlePubMed CentralGoogle Scholar
- Stefani S, Mezzatesta ML, Fadda G, Mattina R, Palù G, Rossano F, et al. Antibacterial activity of cefditoren against major community-acquired respiratory pathogens recently isolated in Italy. J Chemother. 2008;20:561–9.PubMedView ArticlePubMed CentralGoogle Scholar
- Tempera G, Furneri PM, Carlone NA, Cocuzza C, Rigoli R, Musumeci R, et al. Antibiotic susceptibility of respiratory pathogens recently isolated in Italy: focus on cefditoren. J Chemother. 2010;22:153–9.PubMedView ArticlePubMed CentralGoogle Scholar
- Pérez-Trallero E, Martín-Herrero JE, Mazón A, García-Delafuente C, Robles P, Iriarte V, et al. Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007). Antimicrob Agents Chemother. 2010;54:2953–9.PubMedView ArticlePubMed CentralGoogle Scholar
- Smit PW, Lindholm L, Lyytikainen O, Jalava J, Patari-Sampo A, Vuopio J. Epidemiology and emm types of invasive group a streptococcal infections in Finland, 2008-2013. Eur J Clin Microbiol Infect Dis. 2015;34:2131–6.PubMedView ArticlePubMed CentralGoogle Scholar
- Villaseñor-Sierra A, Katahira E, Jaramillo-Valdivia AN, Barajas-García Mde L, Bryant A, Morfín-Otero R, et al. Phenotypes and genotypes of erythromycin-resistant Streptococcus pyogenes strains isolated from invasive and non-invasive infections from Mexico and the USA during 1999-2010. Int J Infect Dis. 2012;16:e178–81.PubMedView ArticlePubMed CentralGoogle Scholar
- Chan JC, Chu YW, Chu MY, Cheung TK, Lo JY. Epidemiological analysis of Streptococcus pyogenes infections in Hong Kong. Pathology. 2009;41:681–6.PubMedView ArticlePubMed CentralGoogle Scholar
- Lu B, Fang Y, Fan Y, Chen X, Wang J, Zeng J, et al. High prevalence of macrolide-resistance and molecular characterization of Streptococcus pyogenes isolates circulating in China from 2009 to 2016. Front Microbiol. 2017;8:1052.PubMedView ArticlePubMed CentralGoogle Scholar
- Pfaller MA, Farrell DJ, Sader HS, Jones RN. AWARE ceftaroline surveillance program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States. Clin Infect Dis. 2012;55(Suppl 3):S187–93.PubMedView ArticlePubMed CentralGoogle Scholar
- Biedenbach DJ, Jones RN, Fritsche TR. Antimicrobial activity of cefditoren tested against contemporary (2004-2006) isolates of Haemophilus influenzae and Moraxella catarrhalis responsible for community-acquired respiratory tract infections in the United States. Diagn Microbiol Infect Dis. 2008;61:240–4.PubMedView ArticlePubMed CentralGoogle Scholar
- Soriano F, Granizo JJ, Coronel P, Gimeno M, Ródenas E, Gracia M, et al. Antimicrobial susceptibility of Haemophilus influenzae, Haemophilus parainfluenzae and Moraxella catarrhalis isolated from adult patients with respiratory tract infections in four southern European countries. The ARISE project. Int J Antimicrob Agents. 2004;23:296–9.PubMedView ArticlePubMed CentralGoogle Scholar
- Càmara J, Marimón JM, Cercenado E, Larrosa N, Quesada MD, Fontanals D, et al. Decrease of invasive pneumococcal disease (IPD) in adults after introduction of pneumococcal 13-valent conjugate vaccine in Spain. PLoS One. 2017;12:e0175224.PubMedView ArticlePubMed CentralGoogle Scholar
- Hays C, Vermee Q, Agathine A, Dupuis A, Varon E, Poyart C, et al. Demonstration of the herd effect in adults after the implementation of pneumococcal vaccination with PCV13 in children. Eur J Clin Microbiol Infect Dis. 2017;36:831–8.PubMedView ArticlePubMed CentralGoogle Scholar
- Regev-Yochay G, Katzir M, Strahilevitz J, Rahav G, Finn T, Miron D, et al. The herd effects of infant PCV7/PCV13 sequential implementation on adult invasive pneumococcal disease, six years post implementation; a nationwide study in Israel. Vaccine. 2017;35:2449–56.PubMedView ArticlePubMed CentralGoogle Scholar
- Carnalla-Barajas MN, Soto-Noguerón A, Sánchez-Alemán MA, Solórzano-Santos F, Velazquez-Meza ME, Echániz-Aviles G, et al. Changing trends in serotypes of S. pneumoniae isolates causing invasive and non-invasive diseases in unvaccinated population in Mexico (2000-2014). Int J Infect Dis. 2017;58:1–7.PubMedView ArticlePubMed CentralGoogle Scholar
- D'Ancona F, Caporali MG, Del Manso M, Giambi C, Camilli R, D'Ambrosio F, et al. Invasive pneumococcal disease in children and adults in seven Italian regions after the introduction of the conjugate vaccine, 2008-2014. Epidemiol Prev. 2015;39(4 Suppl 1):134–8.PubMedPubMed CentralGoogle Scholar
- Ben-Shimol S, Givon-Lavi N, Grisaru-Soen G, Megged O, Greenberg D, Dagan R, et al. Comparative incidence dynamics and serotypes of meningitis, bacteremic pneumonia and other-IPD in young children in the PCV era: insights from Israeli surveillance studies. Vaccine. 2017. https://doi.org/10.1016/j.vaccine.2017.05.059 [Epub ahead of print].PubMedView ArticlePubMed CentralGoogle Scholar
- Gaviria-Agudelo CL, Jordan-Villegas A, Garcia C, Mc Cracken GH Jr. The Effect of 13-valent pneumococcal conjugate vaccine on the serotype distribution and antibiotic resistance profiles in children with invasive pneumococcal disease. J Pediatric Infect Dis Soc. 2016; Epub ahead of print.Google Scholar
- Picazo J, Ruiz-Contreras J, Casado-Flores J, Negreira S, García-de-Miguel MJ, Hernández-Sampelayo T, et al. Expansion of serotype coverage in the universal pediatric vaccination calendar: short-term effects on age- and serotype-dependent incidence of invasive pneumococcal clinical presentations in Madrid, Spain. Clin Vaccine Immunol. 2013;20:1524–30.PubMedView ArticlePubMed CentralGoogle Scholar
- Fenoll A, Granizo JJ, Giménez MJ, Yuste J, Aguilar L. Secular trends (1990-2013) in serotypes and associated non-susceptibility of S. pneumoniae isolates causing invasive disease in the pre−/post-era of pneumococcal conjugate vaccines in Spanish regions without universal paediatric pneumococcal vaccination. Vaccine. 2015;33:5691–9.PubMedView ArticlePubMed CentralGoogle Scholar
- Tarragó D, Aguilar L, García R, Gimenez MJ, Granizo JJ, Fenoll A. Evolution of clonal and susceptibility profiles of serotype 19A Streptococcus pneumoniae among invasive isolates from children in Spain, 1990 to 2008. Antimicrob Agents Chemother. 2011;55:2297–302.PubMedView ArticlePubMed CentralGoogle Scholar
- Beall BW, Gertz RE, Hulkower RL, Whitney CG, Moore MR, Brueggemann AB. Shifting genetic structure of invasive serotype 19A pneumococci in the United States. J Infect Dis. 2011;203:1360–8.PubMedView ArticlePubMed CentralGoogle Scholar
- Reinert R, Jacobs MR, Kaplan SL. Pneumococcal disease caused by serotype 19A: review of the literature and implications for future vaccine development. Vaccine. 2010;28:4249–59.PubMedView ArticlePubMed CentralGoogle Scholar
- Kim L, McGee L, Tomczyk S, Beall B. Biological and epidemiological features of antibiotic-resistant Streptococcus pneumoniae in pre- and post-conjugate vaccine eras: a United States perspective. Clin Microbiol Rev. 2016;29:525–52.PubMedView ArticlePubMed CentralGoogle Scholar
- Tomczyk S, Lynfield R, Schaffner W, Reingold A, Miller L, Petit S, et al. Prevention of antibiotic-nonsusceptible invasive pneumococcal disease with the 13-valent pneumococcal conjugate vaccine. Clin Infect Dis. 2016;62:1119–25.PubMedView ArticlePubMed CentralGoogle Scholar
- Kaur R, Casey JR, Pichichero ME. Emerging Streptococcus pneumoniae strains colonizing the nasopharynx in children after 13-valent pneumococcal conjugate vaccination in comparison to the 7-valent era, 2006-2015. Pediatr Infect Dis J. 2016;35:901–6.PubMedView ArticlePubMed CentralGoogle Scholar
- Kim SH, Song JH, Chung DR, Thamlikitkul V, Yang Y, Wang H, et al. Changing trends in antimicrobial resistance and serotypes of Streptococcus pneumoniae isolates in Asian countries: an Asian network for surveillance of resistant pathogens (ANSORP) study. Antimicrob Agents Chemother. 2012;56:1418–26.PubMedView ArticlePubMed CentralGoogle Scholar
- Phongsamart W, Srifeungfung S, Chatsuwan T, Nunthapisud P, Treerauthaweeraphong V, Rungnobhakhun P, et al. Changing trends in serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae causing invasive diseases in Central Thailand, 2009-2012. Hum Vaccin Immunother. 2014;10:1866–73.PubMedView ArticlePubMed CentralGoogle Scholar
- Biedenbach DJ, Jones RN. Update of cefditoren activity tested against community-acquired pathogens associated with infections of the respiratory tract and skin and skin structures, including recent pharmacodynamic considerations. Diagn Microbiol Infect Dis. 2009;64:202–12.PubMedView ArticlePubMed CentralGoogle Scholar
- Tempera G, Furneri PM, Ferranti C, Genovese C, Ripa S, Ungheri S, et al. In vitro activity of cefditoren versus other antibiotics against S. pneumoniae clinical strains isolated in Italy. Int J Immunopathol Pharmacol. 2010;23:833–40.PubMedView ArticlePubMed CentralGoogle Scholar
- Fenoll A, Giménez MJ, Robledo O, Coronel P, Gimeno M, Casal J, et al. Activity of cefditoren against clinical isolates of Streptococcus pneumoniae showing non-susceptibility to penicillins, cephalosporins, macrolides, ketolides or quinolones. Int J Antimicrob Agents. 2007;29:224–6.PubMedView ArticlePubMed CentralGoogle Scholar
- Fenoll A, Aguilar L, Robledo O, Giménez MJ, Tarragó D, Granizo JJ, et al. Influence of the beta-lactam resistance phenotype on the cefuroxime versus cefditoren susceptibility of Streptococcus pneumoniae and Haemophilus influenzae recovered from children with acute otitis media. J Antimicrob Chemother. 2007;60:323–7.PubMedView ArticlePubMed CentralGoogle Scholar
- Fenoll A, Giménez MJ, Robledo O, Aguilar L, Tarragó D, Granizo JJ, et al. In vitro activity of oral cephalosporins against pediatric isolates of Streptococcus pneumoniae non-susceptible to penicillin, amoxicillin or erythromycin. J Chemother. 2008;20:175–9.PubMedView ArticlePubMed CentralGoogle Scholar
- Fritsche TR, Biedenbach DJ, Jones RN. Update of the activity of cefditoren and comparator oral beta-lactam agents tested against community-acquired Streptococcus pneumoniae isolates (USA, 2004-2006). J Chemother. 2008;20:170–4.PubMedView ArticlePubMed CentralGoogle Scholar
- Seral C, Suárez L, Rubio-Calvo C, Gómez-Lus R, Gimeno M, Coronel P, et al. In vitro activity of cefditoren and other antimicrobial agents against 288 Streptococcus pneumoniae and 220 Haemophilus influenzae clinical strains isolated in Zaragoza, Spain. Diagn Microbiol Infect Dis. 2008;62:210–5.PubMedView ArticlePubMed CentralGoogle Scholar
- Fenoll A, Giménez MJ, Robledo O, Aguilar L, Tarragó D, Granizo JJ, et al. Influence of penicillin/amoxicillin non-susceptibility on the activity of third-generation cephalosporins against Streptococcus pneumoniae. Eur J Clin Microbiol Infect Dis. 2008;27:75–80.PubMedView ArticlePubMed CentralGoogle Scholar
- Lee MY, Ko KS, Oh WS, Park S, Lee JY, Baek JY, et al. In vitro activity of cefditoren: antimicrobial efficacy against major respiratory pathogens from Asian countries. Int J Antimicrob Agents. 2006;28:14–8.PubMedView ArticlePubMed CentralGoogle Scholar
- Yanagihara K, Watanabe A, Aoki N, Matsumoto T, Yoshida M, Sato J, et al. Nationwide surveillance of bacterial respiratory pathogens conducted by the surveillance committee of Japanese Society of Chemotherapy, the Japanese Association for Infectious Diseases, and the Japanese Society for Clinical Microbiology in 2012: general view of the pathogens’ antibacterial susceptibility. J Infect Chemother. 2017;21:410–20.View ArticleGoogle Scholar
- Cafini F, Aguilar L, Alou L, Giménez MJ, Sevillano D, Torrico M, et al. Cidal activity of oral third-generation cephalosporins against Streptococcus pneumoniae in relation to cefotaxime intrinsic activity. Eur J Clin Microbiol Infect Dis. 2008;27:679–83.PubMedView ArticlePubMed CentralGoogle Scholar
- Mezzatesta ML, Gona F, Marchese G, Nicolosi D, Toscano MA, Stefani S, et al. Cefditoren versus community-acquired respiratory pathogens: time-kill studies. J Chemother. 2009;21:378–82.PubMedView ArticlePubMed CentralGoogle Scholar
- García-Cobos S, Campos J, Lázaro E, Román F, Cercenado E, García-Rey C, et al. Ampicillin-resistant non-beta-lactamase-producing Haemophilus influenzae in Spain: recent emergence of clonal isolates with increased resistance to cefotaxime and cefixime. Antimicrob Agents Chemother. 2007;51:2564–73.PubMedView ArticlePubMed CentralGoogle Scholar
- Hotomi M, Fujihara K, Billal DS, Suzuki K, Nishimura T, Baba S, et al. Genetic characteristics and clonal dissemination of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains isolated from the upper respiratory tract of patients in Japan. Antimicrob Agents Chemother. 2007;51:3969–76.PubMedView ArticlePubMed CentralGoogle Scholar
- Barbosa AR, Giufrè M, Cerquetti M, Bajanca-Lavado MP. Polymorphism in ftsI gene and β-lactam susceptibility in Portuguese Haemophilus influenzae strains: clonal dissemination of beta-lactamase-positive isolates with decreased susceptibility to amoxicillin/clavulanic acid. J Antimicrob Chemother. 2011;66:788–96.PubMedView ArticlePubMed CentralGoogle Scholar
- Kim IS, Ki CS, Kim S, Oh WS, Peck KR, Song JH, et al. Diversity of ampicillin resistance genes and antimicrobial susceptibility patterns in Haemophilus influenzae strains isolated in Korea. Antimicrob Agents Chemother. 2007;51:453–60.PubMedView ArticlePubMed CentralGoogle Scholar
- Hasegawa K, Yamamoto K, Chiba N, Kobayashi R, Nagai K, Jacobs MR, et al. Diversity of ampicillin-resistance genes in Haemophilus influenzae in Japan and the United States. Microb Drug Resist. 2003;9:39–46.PubMedView ArticlePubMed CentralGoogle Scholar
- Setchanova LP, Kostyanev T, Alexandrova AB, Mitov IG, Nashev D, Kantardjiev T. Microbiological characterization of Streptococcus pneumoniae and non-typeable Haemophilus influenzae isolates as primary causes of acute otitis media in Bulgarian children before the introduction of conjugate vaccines. Ann Clin Microbiol Antimicrob. 2013;12:6.PubMedView ArticlePubMed CentralGoogle Scholar
- Shiro H, Sato Y, Toyonaga Y, Hanaki H, Sunakawa K. Nationwide survey of the development of drug resistance in the pediatric field in 2000-2001, 2004, 2007, 2010, and 2012: evaluation of the changes in drug sensitivity of Haemophilus influenzae and patients’ background factors. J Infect Chemother. 2015;21:247–56.PubMedView ArticlePubMed CentralGoogle Scholar
- García-Cobos S, Campos J, Cercenado E, Román F, Lázaro E, Pérez-Vázquez M, et al. Antibiotic resistance in Haemophilus influenzae decreased, except for beta-lactamase-negative amoxicillin-resistant isolates, in parallel with community antibiotic consumption in Spain from 1997 to 2007. Antimicrob Agents Chemother. 2008;52:2760–6.PubMedView ArticlePubMed CentralGoogle Scholar
- García-Cobos S, Arroyo M, Pérez-Vázquez M, Aracil B, Lara N, Oteo J, et al. Isolates of β-lactamase-negative ampicillin-resistant Haemophilus influenzae causing invasive infections in Spain remain susceptible to cefotaxime and imipenem. J Antimicrob Chemother. 2014;69:111–6.PubMedView ArticlePubMed CentralGoogle Scholar
- Resman F, Ristovski M, Forsgren A, Kaijser B, Kronvall G, Medstrand P, et al. Increase of β-lactam-resistant invasive Haemophilus influenzae in Sweden, 1997 to 2010. Antimicrob Agents Chemother. 2012;56:4408–15.PubMedView ArticlePubMed CentralGoogle Scholar
- Hu J, Wang XL, Xu F, Xie J, Liu HW, Yang LL, et al. Epidemiological survey of Haemophilus influenzae-positive hospitalized children: a retrospective analysis [Chinese]. Zhongguo Dang Dai Er Ke Za Zhi. 2015;17:596–601.PubMedPubMed CentralGoogle Scholar
- García-Cobos S, Campos J, Román F, Carrera C, Pérez-Vázquez M, Aracil B, et al. Low beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains are best detected by testing amoxicillin susceptibility by the broth microdilution method. Antimicrob Agents Chemother. 2008;52:2407–11.PubMedView ArticlePubMed CentralGoogle Scholar
- Sevillano D, Giménez MJ, Cercenado E, Cafini F, Gené A, Alou L, et al. Genotypic versus phenotypic characterization, with respect to beta-lactam susceptibility, of Haemophilus influenzae isolates exhibiting decreased susceptibility to beta-lactam resistance markers. Antimicrob Agents Chemother. 2009;53:267–70.PubMedView ArticlePubMed CentralGoogle Scholar
- Yang Q, Xu Y, Chen M, Wang H, Sun H, Hu Y, et al. In vitro activity of cefditoren and other comparators against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis causing community-acquired respiratory tract infections in China. Diagn Microbiol Infect Dis. 2012;73:187–91.PubMedView ArticlePubMed CentralGoogle Scholar
- Ulloa C, Guevara S, Soley C, Abdelnour A, Arguedas A. In vitro activity of cefditoren against middle ear fluid isolates from Costa Rican children with otitis media. Chemotherapy. 2014;60:211–8.PubMedView ArticlePubMed CentralGoogle Scholar
- Tristram S, Jacobs MR, Appelbaum PC. Antimicrobial resistance in Haemophilus influenzae. Clin Microbiol Rev. 2007;20:368–89.PubMedView ArticlePubMed CentralGoogle Scholar
- Soriano F, Giménez MJ, Aguilar L. Cefditoren in upper and lower community-acquired respiratory tract infections. Drug Des Devel Ther. 2011;5:85–94.PubMedView ArticlePubMed CentralGoogle Scholar
- Barberán J, Aguilar L, Giménez MJ. Update on the clinical utility and optimal use of cefditoren. Int J Gen Med. 2012;5:455–64.PubMedPubMed CentralGoogle Scholar
- Aguilar L, Giménez MJ, Barberán J. Drug resistance in community-acquired respiratory tract infections: role for an emerging antibacterial. Infect Drug Resist. 2010;3:35–43.PubMedView ArticlePubMed CentralGoogle Scholar
- Turnidge J, Paterson DL. Setting and revising antibacterial susceptibility breakpoints. Clin Microbiol Rev. 2007;20:391–408.PubMedView ArticlePubMed CentralGoogle Scholar
- Cafini F, González N, Torrico M, Echeverría O, Sevillano D, Alou L, et al. Influence of the displacement of protein binding by ibuprofen in the activity of a third-generation cephalosporin against Streptococcus pneumoniae [article in Spanish]. Rev Esp Quimioter. 2006;19:332–6.PubMedPubMed CentralGoogle Scholar
- Sevillano D, Giménez MJ, Alou L, Aguilar L, Cafini F, Torrico M, et al. Effects of human albumin and serum on the in vitro bactericidal activity of cefditoren against penicillin-resistant Streptococcus pneumoniae. J Antimicrob Chemother. 2007;60:156–8.PubMedView ArticlePubMed CentralGoogle Scholar
- Sevillano D, Aguilar L, Alou L, Giménez MJ, González N, Torrico M, et al. High protein binding and cidal activity against penicillin-resistant S. pneumoniae: a cefditoren in vitro pharmacodynamic simulation. PLoS One. 2008;3:e2717.PubMedView ArticlePubMed CentralGoogle Scholar
- Torrico M, Aguilar L, González N, Giménez MJ, Echeverría O, Cafini F, et al. Influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhibiting an N526K mutation in the ftsI gene. Antimicrob Agents Chemother. 2007;51:3699–706.PubMedView ArticlePubMed CentralGoogle Scholar
- Sevillano D, Aguilar L, Alou L, Giménez MJ, González N, Echeverría O, et al. Beta-lactam activity against penicillin-resistant Streptococcus pneumoniae strains exhibiting higher amoxicillin versus penicillin minimum inhibitory concentration values: an in vitro pharmacodynamic simulation. Chemotherapy. 2008;54:84–90.PubMedView ArticlePubMed CentralGoogle Scholar
- Cafini F, Aguilar L, Sevillano D, Giménez MJ, Alou L, Fenoll A, et al. Decrease in bacterial load versus resistance selection of pneumococcal subpopulations by beta-lactam physiological concentrations over time: an in vitro pharmacodynamic simulation. Microb Drug Resist. 2008;14:13–21.PubMedView ArticlePubMed CentralGoogle Scholar
- Alou L, Giménez MJ, Sevillano D, Aguilar L, González N, Echeverría O, et al. Are beta-lactam breakpoints adequate to define non-susceptibility for all Haemophilus influenzae resistance phenotypes from a pharmacodynamic point of view? J Antimicrob Chemother. 2007;59:652–7.PubMedView ArticlePubMed CentralGoogle Scholar
- González N, Aguilar L, Alou L, Giménez MJ, Sevillano D, Torrico M, et al. Influence of different resistance traits on the competitive growth of Haemophilus influenzae in antibiotic-free medium and selection of resistant populations by different β-lactams: an in vitro pharmacodynamic approach. J Antimicrob Chemother. 2009;63:1215–22.PubMedView ArticlePubMed CentralGoogle Scholar
- Sevillano D, Aguilar L, Alou L, Giménez MJ, González N, Torrico M, et al. Beta-lactam effects on mixed cultures of common respiratory isolates as an approach to treatment effects on nasopharyngeal bacterial population dynamics. PLoS One. 2008;3:e3846.PubMedView ArticlePubMed CentralGoogle Scholar
- González N, Aguilar L, Sevillano D, Giménez MJ, Alou L, Cafini F, et al. Efficacy of simulated cefditoren versus amoxicillin-clavulanate free concentrations in countering intrastrain ftsI gene diffusion in Haemophilus influenzae. Antimicrob Agents Chemother. 2011;55:2788–94.PubMedView ArticlePubMed CentralGoogle Scholar
- Ramos-Sevillano E, Rodríguez-Sosa C, Cafini F, Giménez MJ, Navarro A, Sevillano D, et al. Cefditoren and ceftriaxone enhance complement-mediated immunity in the presence of specific antibodies against antibiotic-resistant pneumococcal strains. PLoS One. 2012;7:e44135.PubMedView ArticlePubMed CentralGoogle Scholar
- Cafini F, Yuste J, Giménez MJ, Sevillano D, Aguilar L, Alou L, et al. Enhanced in vivo activity of cefditoren in pre-immunized mice against penicillin-resistant S. pneumoniae (serotypes 6B, 19F and 23F) in a sepsis model. PLoS One. 2010;5:e12041.PubMedView ArticlePubMed CentralGoogle Scholar
- Granizo JJ, Sádaba B, Honorato J, Gimenez MJ, Sevillano D, Aguilar L, et al. Monte Carlo simulation describing the pharmacodynamic profile of cefditoren in plasma from healthy volunteers. Int J Antimicrob Agents. 2008;31:396–8.PubMedView ArticlePubMed CentralGoogle Scholar
- Wellington K, Curran MP. Cefditoren pivoxil: a review of its use in the treatment of bacterial infections. Drugs. 2004;64:2597–618.PubMedView ArticlePubMed CentralGoogle Scholar
- Food and Drug Administration. Spectracef prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021222s009lbl.pdf
- Lodise TP, Kinzig-Schippers M, Drusano GL, Loos U, Vogel F, Bulitta J, et al. Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid. Antimicrob Agents Chemother. 2008;52:1945–51.PubMedView ArticlePubMed CentralGoogle Scholar
- Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26:1–10.PubMedView ArticlePubMed CentralGoogle Scholar
- Craig WA. Pharmacodynamics of antimicrobials: General concepts and applications. In: Nightingale CH, Murakawa T, Ambrose PG, editors. Antimicrobial pharmacodynamics in theory and clinical practice. New York: Marcel Dekker, Inc; 2001.Google Scholar
- Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; nineteenth informational supplement. CLSI document M100-S19. Wayne: Clinical and Laboratory Standards Institute; 2009.Google Scholar
- Food and Drug Administration. Microbiology Data for Systemic Antibacterial Drugs — Development, Analysis, and presentation: Guidance for industry; 2016. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM182288.pdf
- Karlowsky JA, Jones ME, Draghi DC, Critchley IA, Thornsberry C, Sahm DF. In vitro susceptibility of recent clinical isolates of pneumococci to the investigational cephalosporin cefditoren. Diagn Microbiol Infect Dis. 2002;42:59–64.PubMedView ArticlePubMed CentralGoogle Scholar
- Johnson DM, Biedenbach DJ, Beach ML, Pfaller MA, Jones RN. Antimicrobial activity and in vitro susceptibility test development for cefditoren against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus species. Diagn Microbiol Infect Dis. 2000;37:99–105.PubMedView ArticlePubMed CentralGoogle Scholar
- Jones RN, Biedenbach DJ, Croco MA, Barrett MS. In vitro evaluation of a novel orally administered cephalosporin (Cefditoren) tested against 1249 recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae. Diagn Microbiol Infect Dis. 1998;31:573–8.PubMedView ArticlePubMed CentralGoogle Scholar
- Agencia Española de Medicamentos y Productos Sanitarios. Meiact ficha técnica https://www.aemps.gob.es/cima/pdfs/es/ft/65975/FichaTecnica_65975.html.pdf
- Sádaba B, Azanza JR, Quetglas EG, Campanero MA, Honorato J, Coronel P, et al. Pharmacokinetic/pharmacodynamic serum and urine profile of cefditoren following single-dose and multiple twice- and thrice-daily regimens in healthy volunteers: a phase I study. Rev Esp Quimioter. 2007;20:51–60.PubMedPubMed CentralGoogle Scholar
- Ball P, Baquero F, Cars O, File T, Garau J, Klugman K, et al. Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. J Antimicrob Chemother. 2002;49:31–40.PubMedView ArticlePubMed CentralGoogle Scholar
- Granizo JJ, Giménez MJ, Barberán J, Coronel P, Gimeno M, Aguilar L. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials. Clin Ther. 2006;28:2061–9.PubMedView ArticlePubMed CentralGoogle Scholar
- Granizo JJ, Giménez MJ, Barberán J, Coronel P, Gimeno M, Aguilar L. Efficacy of cefditoren in the treatment of upper respiratory tract infections: a pooled analysis of six clinical trials. Rev Esp Quimioter. 2008;21:14–21.PubMedPubMed CentralGoogle Scholar
- Kaplan EL, Tucker RM, Poling TL, Marsh D, Chou C. A multicenter comparison of cefditoren pivoxil and penicillin VK. J Respir Dis. 2001;22(Suppl):S60–4.Google Scholar
- Gooch W, Marsh D, Slickler T, Hunt B. Cefditoren is safe and effective treatment for streptococcal pharyngitis. Toronto: Poster presented at: Fortyth Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000. Abstract 837Google Scholar
- Chow J, Russell M, Volk S, Chow C. Efficacy of cefditoren pivoxil (CDTR) versus amoxicillin/clavulanate (AMX/CLV) in acute maxillary sinusitis (AMS). Toronto: Poster presented at: Fortyth Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000. Abstract 835Google Scholar
- Alvarez-Sala JL, Kardos P, Martínez-Beltrán J, Coronel P, Aguilar L. Clinical and bacteriological efficacy in treatment of acute exacerbations of chronic bronchitis with cefditoren-pivoxil versus cefuroxime-axetil. Antimicrob Agents Chemother. 2006;50:1762–7.PubMedView ArticlePubMed CentralGoogle Scholar
- Ramírez JA, Tucker RM, Bettis RB, Cyganousky M, Hunt BJ. Treating acute exacerbations of chronic bronchitis. J Resp Dis. 2001;22(Suppl. 8):S75–80.Google Scholar
- Henry DC, Poling TL, Bettis RB, Junt BJ, Cyganouski M, Hom RC. A double-blind, randomized study of cefditoren vs. cefuroxime for AECB. J Resp Dis. 2001;22(Suppl. 8):S69–74.Google Scholar
- Blasi F, Tarsia P, Mantero M, Morlacchi LC, Piffer F. Cefditoren versus levofloxacin in patients with exacerbations of chronic bronchitis: serum inflammatory biomarkers, clinical efficacy, and microbiological eradication. Ther Clin Risk Manag. 2013;9:55–64.PubMedView ArticlePubMed CentralGoogle Scholar
- Fogarty CM, Cyganowski M, Palo WA, Hom RC, Craig WA. A comparison of cefditoren pivoxil and amoxicillin/ clavulanate in the treatment of community-acquired pneumonia: a multicenter, prospective, randomized, investigator-blinded, parallel-group study. Clin Ther. 2002;24:1854–70.PubMedView ArticlePubMed CentralGoogle Scholar
- van Zyl L, le Roux JG, LaFata JA, Volk RS, Palo WA, Flamm R, et al. Cefditoren pivoxil versus cefpodoxime proxetil for community-acquired pneumonia: results of a multicenter, prospective, randomized, double-blind study. Clin Ther. 2002;24:1840–53.PubMedView ArticlePubMed CentralGoogle Scholar
- Brook I. Treatment challenges of group a Beta-hemolytic streptococcal pharyngo-tonsillitis. Int Arch Otorhinolaryngol. 2017;21:286–96.PubMedView ArticlePubMed CentralGoogle Scholar
- Camilli R, Vescio MF, Giufrè M, Daprai L, Garlaschi ML, Cerquetti M, et al. Carriage of Haemophilus influenzae is associated with pneumococcal vaccination in Italian children. Vaccine. 2015;33:4559–64.PubMedView ArticlePubMed CentralGoogle Scholar
- Medaney F, Dimitriu T, Ellis RJ, Raymond B. Live to cheat another day: bacterial dormancy facilitates the social exploitation of β-lactamases. ISME J. 2016;10:778–87.PubMedView ArticlePubMed CentralGoogle Scholar
- Budhani RK, Struthers JK. Interaction of Streptococcus pneumoniae and Moraxella catarrhalis: investigation of the indirect pathogenic role of beta-lactamase-producing moraxellae by use of a continuous-culture biofilm system. Antimicrob Agents Chemother. 1998;42:2521–6.PubMedView ArticlePubMed CentralGoogle Scholar
- Lewnard JA, Huppert A, Givon-Lavi N, Pettigrew MM, Regev-Yochay G, Dagan R, et al. Density, serotype diversity, and fitness of Streptococcus pneumoniae in upper respiratory tract cocolonization with nontypeable Haemophilus influenzae. J Infect Dis. 2016;214:1411–20.PubMedView ArticlePubMed CentralGoogle Scholar
- Weimer KE, Armbruster CE, Juneau RA, Hong W, Pang B, Swords WE. Coinfection with Haemophilus influenzae promotes pneumococcal biofilm formation during experimental otitis media and impedes the progression of pneumococcal disease. J Infect Dis. 2010;202:1068–75.PubMedView ArticlePubMed CentralGoogle Scholar
- Prince AS. Biofilms, antimicrobial resistance, and airway infection. N Engl J Med. 2002;347:1110–1.PubMedView ArticlePubMed CentralGoogle Scholar
- Dy R, Sethi S. The lung microbiome and exacerbations of COPD. Curr Opin Pulm Med. 2016;22:196–202.PubMedView ArticlePubMed CentralGoogle Scholar
- Shukla SD, Fairbairn RL, Gell DA, Latham RD, Sohal SS, Walters EH, et al. An antagonist of the platelet-activating factor receptor inhibits adherence of both nontypeable Haemophilus influenzae and Streptococcus pneumoniae to cultured human bronchial epithelial cells exposed to cigarette smoke. Int J Chron Obstruct Pulmon Dis. 2016;11:1647–55.PubMedView ArticlePubMed CentralGoogle Scholar
- Bellinghausen C, Gulraiz F, Heinzmann AC, Dentener MA, Savelkoul PH, Wouters EF, et al. Exposure to common respiratory bacteria alters the airway epithelial response to subsequent viral infection. Respir Res. 2016;17:68.PubMedView ArticlePubMed CentralGoogle Scholar
- Swords WE. Nontypeable Haemophilus influenzae biofilms: role in chronic airway infections. Front Cell Infect Microbiol. 2012;2:97.PubMedPubMed CentralGoogle Scholar
- Murphy TF, Kirkham C, Sethi S, Lesse AJ. Expression of a peroxiredoxin-glutaredoxin by Haemophilus influenzae in biofilms and during human respiratory tract infection. FEMS Immunol Med Microbiol. 2005;44:81–9.PubMedView ArticlePubMed CentralGoogle Scholar
- Ahearn CP, Gallo MC, Murphy TF. Insights on persistent airway infection by non-typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Pathog Dis. 2017;75(4).Google Scholar
- Pang B, Hong W, West-Barnette SL, Kock ND, Swords WE. Diminished ICAM-1 expression and impaired pulmonary clearance of nontypeable Haemophilus influenzae in a mouse model of chronic obstructive pulmonary disease/emphysema. Infect Immun. 2008;76:4959–67.PubMedView ArticlePubMed CentralGoogle Scholar
- Sethi S. Infection as a comorbidity of COPD. Eur Respir J. 2010;35:1209–10.PubMedView ArticlePubMed CentralGoogle Scholar
- Roveta S, Schito AM, Marchese A, Schito GC. Activity of moxifloxacin on biofilms produced in vitro by bacterial pathogens involved in acute exacerbations of chronic bronchitis. Int J Antimicrob Agents. 2007;30:415–21.PubMedView ArticlePubMed CentralGoogle Scholar
- Maestre JR, Mateo M, Méndez ML, Aguilar L, Gimenez MJ, Alou L, et al. In vitro interference of beta-lactams with biofilm development by prevalent community respiratory tract isolates. Int J Antimicrob Agents. 2010;35:274–7.PubMedView ArticlePubMed CentralGoogle Scholar
- Di Marco F, Braido F, Santus P, Scichilone N, Blasi F. The role of cefditoren in the treatment of lower community-acquired respiratory tract infections (LRTIs): from bacterial eradication to reduced lung inflammation and epithelial damage. Eur Rev Med Pharmacol Sci 2014;18:321–332.Google Scholar
- Duell BL, Su YC, Riesbeck K. Host-pathogen interactions of nontypeable Haemophilus influenzae: from commensal to pathogen. FEBS Lett. 2016;590:3840–53.PubMedView ArticlePubMed CentralGoogle Scholar
- Sethi S. Bacteria in exacerbations of chronic obstructive pulmonary disease: phenomenon or epiphenomenon? Proc Am Thorac Soc. 2004;1:109–14.PubMedView ArticlePubMed CentralGoogle Scholar
- Pragman AA, Berger JP, Williams BJ. Understanding persistent bacterial lung infections: clinical implications informed by the biology of the microbiota and biofilms. Clin Pulm Med. 2016;23:57–66.PubMedView ArticlePubMed CentralGoogle Scholar
- Domenech A, Ardanuy C, Pallares R, Grau I, Santos S, De la Campa AG, et al. Some pneumococcal serotypes are more frequently associated with relapses of acute exacerbations in COPD patients. PLoS One. 2013;8:e59027.PubMedView ArticlePubMed CentralGoogle Scholar
- Canut A, Martín-Herrero JE, Labora A, Maortua H. What are the most appropriate antibiotics for the treatment of acute exacerbation of chronic obstructive pulmonary disease? A therapeutic outcomes model. J Antimicrob Chemother. 2007;60:605–12.PubMedView ArticlePubMed CentralGoogle Scholar
- Pettigrew MM, Tsuji BT, Gent JF, Kong Y, Holden PN, Sethi S, et al. Effect of fluoroquinolones and macrolides on eradication and resistance of Haemophilus influenzae in chronic obstructive pulmonary disease. Antimicrob Agents Chemother. 2016;60:4151–8.PubMedView ArticlePubMed CentralGoogle Scholar
- Blasi F, Concia E, Del Prato B, Giusti M, Mazzei T, Polistena B, et al. The most appropriate therapeutic strategy for acute lower respiratory tract infections: a Delphi-based approach. J Chemother. 2017;15:1–13.Google Scholar
- Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2):S27–72.View ArticleGoogle Scholar
- Bosso JA, Drew RH. Application of antimicrobial stewardship to optimise management of community acquired pneumonia. Int J Clin Pract. 2011;65:775–83.PubMedView ArticlePubMed CentralGoogle Scholar
- González-Castillo J, Martín-Sánchez FJ, Llinares P, Menéndez R, Mujal A, Navas E, et al. Guidelines for the management of community-acquired pneumonia in the elderly patient. Rev Esp Quimioter. 2014;27:69–86.PubMedPubMed CentralGoogle Scholar
- Menendez R, Montull B, Mendez R. Antibiotic choice, route and duration: minimizing the harm associated with antibiotics. In: Chalmers JD, Pletz MW, Aliberti S, editors. Community-Acquired Pneumonia. Eur Respir Mon. 2014. p. 155–67.Google Scholar
- Barberán J, Mensa J. Cefditoren and community-acquired lower respiratory tract infections [article in Spanish]. Rev Esp Quimioter. 2009;22:144–50.PubMedPubMed CentralGoogle Scholar
- Athanassa Z, Makris G, Dimopoulos G, Falagas ME. Early switch to oral treatment in patients with moderate to severe community-acquired pneumonia: a meta-analysis. Drugs. 2008;68:2469–81.PubMedView ArticlePubMed CentralGoogle Scholar
- Asche C, McAdam-Marx C, Seal B, Crookston B, Mullins CD. Treatment costs associated with community-acquired pneumonia by community level of antimicrobial resistance. J Antimicrob Chemother. 2008;61:1162–8.PubMedView ArticlePubMed CentralGoogle Scholar
- Tillotson GS, Zinner SH. Burden of antimicrobial resistance in an era of decreasing susceptibility. Expert Rev Anti-Infect Ther. 2017;15:663–76.PubMedView ArticlePubMed CentralGoogle Scholar
- Martin M, Quilici S, File T, Garau J, Kureishi A, Kubin M. Cost-effectiveness of empirical prescribing of antimicrobials in community-acquired pneumonia in three countries in the presence of resistance. J Antimicrob Chemother. 2007;59:977–89.PubMedView ArticlePubMed CentralGoogle Scholar
- Granizo JJ, Rodicio MP. Ecology, antibiotics and biodiversity. In: SiCom XXISL, editor. From microbiology to clinical practice: the cefditoren case. Madrid; 2009. p. 225–35.Google Scholar
- Giménez MJ, Aguilar L. Can ecology be a parameter for antibiotic election? In: SiCom XXISL, editor. From microbiology to clinical practice: the cefditoren case. Madrid; 2009. p. 253–9.Google Scholar
- Aguilar L, Giménez MJ. Gaps in antibiotic development: the post-marketing task. Rev Med Microbiol. 2008;19:1–7.View ArticleGoogle Scholar
- From microbiology to clinical practice: The cefditoren case. SiCom XXI SL: Madrid, 2009.Google Scholar
- From microbiology to clinical practice: The cefditoren case II. SiCom XXI SL, Madrid;2012.Google Scholar